Left atrial appendage closure (LAAC) does not replace oral anticoagulation therapy for stroke prevention in high-risk cardiac surgery patients with atrial fibrillation, according to recent clinical findings and cardiovascular research. While surgical or minimally invasive closure of the left atrial appendage successfully seals off a primary site for blood clot formation, clinical evaluations indicate that the procedure remains reserved primarily for patients with specific high-risk profiles rather than serving as a universal substitute for blood thinners.
Understanding Left Atrial Appendage Closure Mechanisms
Left atrial appendage closure involves sealing off or removing the left atrial appendage, a small muscular pouch in the wall of the heart’s top left chamber. According to the Cleveland Clinic, normal hearts contract with each heartbeat to squeeze blood out of the atrium and into the ventricle, but atrial fibrillation causes fast, chaotic electrical impulses that disrupt this normal squeezing action.
Because the left atrial appendage is a pouch, blood can collect and form clots during irregular heart rhythms. Patients with atrial fibrillation face a stroke risk three to five times higher than the general population. To mitigate this risk, clinicians utilize various closure devices. Devices that block the opening include the WATCHMAN, Amulet, and WaveCrest systems. Other options include the AtriClip device, which clamps the base of the appendage, and suture-loop systems like the Lariat.
Comparative Outcomes in Clinical Trials
Clinical investigations continue to evaluate how mechanical closure compares to standard pharmaceutical therapies. The randomized PRAGUE-17 trial demonstrated the noninferiority of left atrial appendage closure to non-vitamin K oral anticoagulants (NOACs) for preventing major cardiovascular and cerebrovascular events. However, researchers examined whether the structural change influenced heart failure biomarkers.
The study analyzed biomarkers in 144 patients out of 402 randomized participants, comparing 73 patients in the NOAC group and 71 in the LAAC group. Investigators measured serum concentrations of NT-proBNP, NT-proANP, Galectin-3, and GDF-15 at baseline, six months, and 24 months. The findings revealed no significant differences in biomarker concentrations between the two cohorts, indicating that left atrial appendage closure did not significantly influence heart failure biomarker levels six months post-procedure.
Indications and Patient Considerations
Medical providers generally recommend sealing off the left atrial appendage for patients who have an increased risk of stroke due to atrial fibrillation and face complications with blood thinners. Many patients encounter difficulties with warfarin, which requires regular blood monitoring, strict limits on vitamin K consumption, and carries an elevated bleeding risk for individuals susceptible to falls or gastrointestinal bleeding. Similarly, while non-vitamin K oral anticoagulants offer alternatives, some patients experience intolerance, high costs, or persistent bleeding concerns.
Despite these device options, it is emphasized that left atrial appendage closure treats stroke risk rather than the underlying atrial fibrillation rhythm itself. Consequently, surgical teams carefully weigh procedural risks against the long-term benefits for each individual patient.